Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers

Kidney International

Volumn 64, Issue 6, 2003, Pages 2272-2279

  Larsson, Tobias ^b   Nisbeth, Ulf ^b   Ljunggren, Östen ^b   Jüppner, Harald ^b   Jonsson, Kenneth B ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

FGF 23; Hyperphosphatemia; Phosphate homeostasis; Phosphate loading; Renal disease

Indexed keywords

CALCITRIOL; CALCIUM; CREATININE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD ANALYSIS; CARBOXY TERMINAL SEQUENCE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT; MALE; PHOSPHATE EXCRETION; PHOSPHATE INTAKE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0344945402     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00328.x     Document Type: Article

References (19)

1. LOCATELLI F, CANNATA-ANDIA JB, DRUEKE TB, et al: Management of disturbances of calcium and phosphate metabolism in chronic renl insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 17:723-731, 2002
2. QUNIBI WY, NOLAN CA, AYUS JC: Cardiovascular calcification in patients with end-stage renal disease: A century-old phenomenon. Kidney Int 62 (Suppl 82):73-80, 2002
3. CANNATA-ANDIA JB, RODRIGUEZ-GARCIA M: Hyperphosphataemia as a cardiovascular risk factor - How to manage the problem. Nephrol Dial Transplant 17:16-19, 2002
4. STREWLER GJ: FGF23, hypophosphatemia, and rickets: Has phosphatonin been found? Proc Natl Acad Sci USA 98:5945-5946, 2001
5. SHIMADA T, MUTO T, URAKAWA I, et al: Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143:3179-3182, 2002
6. SHIMADA T, MIZUTANI S, MUTO T, et al: Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500-6505, 2001
7. SHIMADA T, YONEYA T, HINO R, et al: Transgenic mice expressing fibroblast growth factor 23 (FGF23) demonstrate hypophosphatemia with low serum 1,25-dihydroxyvitamin D [1,25(OH)2D] and rickets/osteomalacia. J Bone Miner Res 16:S151, 2001
8. SHIMADA T, KAKITANI M, HASEGAWA H, et al: Targeted ablation of FGF-23 causes hyperphosphatemia, increased 1,25 dihydroxyvitamin D level and severe growth retardation. J Bone Miner Res 17:S168,2002
9. WHITE KE, JONSSON KB, CARN G, et al: The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 86:497-500, 2001
10. LARSSON T, ZAHRADNIK R, LAVIGNE J, et al: Immunohistochemical detection of FGF-23 protein in tumors that cause oncogenic osteomalacia. Eur J Endocrinol 148:269-276, 2003
11. JONSSON KB, ZAHRADNIK R, LARSSON T, et al: Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656-1663, 2003
12. YAMAZAKI Y, OKAZAKI R, SHIBATA M, et al: Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957-4960, 2002
13. DOMINGUEZ JH, GRAY RW, LEMANN J, JR: Dietary phosphate deprivation in women and men: effects on mineral and acid balances, parathyroid hormone and the metabolism of 25-OH-vitamin D. J Clin Endocrinol Metab 43:1056-1068, 1976
14. YAMASHITA T, HASEGAVVA H, YAMAZAKI Y, et al: Involvement of FGF-23 in abnormal vitamin D and mineral metabolism associated with renal insufficiency. ASN Renal Week (vol SU-P0534), Philadelphia, 2002
15. LEAVEY SF, WEITZEL WF: Endocrine abnormalities in chronic renal failure. Endocrinol Metab Clin North Am 31:107-119, 2002
16. KAZAMA JJ, SHIGEMATSU T, YANO K, et al: Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 39:525-532, 2002
17. SHIMADA T, HASEGAWA H, YAMAZAKI Y, et al: FGF-23 is a novel humoral factor regulating vitamin D metabolism. ASN Renal Week (vol SA-FC135), Philadelphia, 2002
18. COLLINS JF, BULUS N, GHISHAN FK: Sodium-phosphate transporter adaptation to dietary phosphate deprivation in normal and hypophosphatemic mice. Am J Physiol 268:G917-G924, 1995
19. ALLEN HC, WHYBRO A, BARKER ME, et al: Endocrine response to escalating-dose phosphate supplementation in men: Is FGF-23 phosphatonin? J Bone Miner Res 17:S159, 2002